三联疗法对尿路上皮与非尿路上皮膀胱癌生存的影响
基于SEER数据库(2004-2020)5130例接受三联疗法(TMT)的cT2-T4N0-N3M0膀胱癌患者,比较尿路上皮癌(UCUB)与非UCUB的肿瘤特异性死亡率无生存(CSM-FS)。器官局限(OC)期非UCUB的CSM-FS中位36个月 vs UCUB 60个月(P=0.01),多变量Cox模型中非UCUB组织学独立预测更高CSM(HR 1.45,P=0.004);非器官局限(NOC)期两组中位CSM-FS均为23个月(P=0.9)。
要点
- OC期非UCUB患者TMT后CSM-FS中位36个月,UCUB为60个月(P=0.01)。
- OC期多变量Cox模型中非UCUB组织学独立预测更高CSM(HR 1.45,P=0.004)。
- NOC期UCUB与非UCUB中位CSM-FS均为23个月(P=0.9)。
核心结论
- OC期UCUB的TMT使用率随时间以符合指南的方式增加。
- OC期非UCUB接受TMT者较OC期UCUB存在CSM劣势。
- NOC期无论UCUB还是非UCUB组织学,TMT的CSM结果均不理想。
研究设计与样本
- 基于监测、流行病学和最终结果(SEER)数据库(2004-2020)识别cT2-T4N0-N3M0膀胱癌接受TMT的患者。
- TMT定义为经尿道膀胱肿瘤切除术、化疗和放疗的联合。
- 可评估的TMT治疗患者共5130例,其中非UCUB 425例(8%),UCUB 4705例(92%)。
- 采用Kaplan-Meier曲线和多变量Cox回归(MCR)模型分析OC与NOC分期下UCUB vs 非UCUB的CSM。
主要发现
- OC期UCUB的TMT率从92.4%升至96.8%(估计年度百分比变化0.4%,P < 0.001),NOC期无此趋势(P = 0.3)。
- OC期非UCUB的CSM-FS中位36个月 vs UCUB 60个月(P = 0.01)。
- NOC期UCUB与非UCUB的CSM-FS中位均为23个月(P = 0.9)。
- OC期MCR模型中非UCUB组织学独立预测更高CSM(HR 1.45,P = 0.004),NOC期无此关联(P = 0.9)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To address cancer-specific mortality free-survival (CSM-FS) differences in patients with urothelial carcinoma of the urinary bladder (UCUB) vs non-UCUB who underwent trimodal therapy (TMT), according to organ confined (OC: T2N0M0) vs non-organ confined (NOC: T3-4NanyM0 or TanyN1-3M0) clinical stages. PATIENTS AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified patients with cT2-T4N0-N3M0 bladder cancer treated with TMT, defined as the combination of transurethral resection of bladder tumour, chemotherapy, and radiotherapy. Temporal trends described TMT use over time. Kaplan-Meier plots and multivariable Cox regression (MCR) models addressed CSM in UCUB vs non-UCUB according to OC vs NOC stages. RESULTS: Of 5130 assessable TMT-treated patients, 425 (8%) harboured non-UCUB vs 4705 (92%) who had UCUB. The TMT rates increased for patients with OC UCUB from 92.4% to 96.8% (estimated annual percentage change of 0.4%, P < 0.001), but not in the NOC stages (P = 0.3). In the OC stage, the median CSM-FS was 36 months in patients with non-UCUB vs 60 months in those with UCUB, respectively (P = 0.01). Conversely, in the NOC stage, the median CSM-FS was 23 months both in UCUB and non-UCUB (P = 0.9). In the MCR models addressing OC stage, non-UCUB histology independently predicted higher CSM (hazard ratio 1.45, P = 0.004), but not in the NOC stage (P = 0.9). CONCLUSION: In OC UCUB, TMT rates have increased over time in a guideline-consistent fashion. Patients with OC non-UCUB treated with TMT showed a CSM disadvantage relative to OC UCUB. In the NOC stage, use of TMT resulted in dismal CSM, regardless of UCUB vs non-UCUB histology.
引用
- de Angelis M, Baudo A, Siech C, et al. Trimodal therapy effect on survival in urothelial vs non-urothelial bladder cancer. BJU Int. 2024. PMID: 38494989. doi:10.1111/bju.16333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。